SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3065-3072. Prepublished online as a Blood First Edition Paper on July 23, 2008; DOI 10.1182/blood-2008-03-143537. This Article Full Text (PDF) All Versions of this Article: blood-2008-03-143537v1 112/8/3065    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kiladjian, J.-J. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Kiladjian, J.-J. Articles by Fenaux, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 7, 2008 Accepted July 14, 2008 Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera Jean-Jacques Kiladjian*, Bruno Cassinat, Sylvie Chevret, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Bernard Grandchamp, Christine Chomienne, and Pierre Fenaux Service d'Hematologie Clinique, AP-HP, Hopital Avicenne; Universite Paris 13, Bobigny, France Unite de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France DBIM, AP-HP, Hopital Saint-Louis, Paris, France Service d'Hematologie, CHU Dupuytren, Limoges, France Service des Maladies du Sang, CHRU de Lille, Hopital Huriez, Lille, France Service d'Hematologie, CHU Purpan,, Toulouse, France Service d'Hematologie, AP-HP, Hopital Lariboisiere, Paris, France Service de Biochimie Hormonale et Génétique, INSERM U656; AP-HP, Hopital Bichat; Universite Paris 7, Paris, France * Corresponding author; email: jean-jacques.kiladjian{at}avc.aphp.fr. Interferon- (IFN) is a non-leukemogenic treatment of polycythemia vera (PV), able to induce cytogenetic remissions. Its use is nevertheless limited by toxicity, leading to treatment discontinuation in about 20% of patients. We completed a phase 2 multicenter study of pegylated-IFN-2a in 40 PV patients. Objectives included evaluation of efficacy, safety, and monitoring of residual disease using JAK2V617F quantification (%V617F). Median follow-up was 31.4 months. At 12 months, all the 37 evaluable patients had hematological response, including 94.6% complete responses (CR). Only 3 patients (8%) had stopped treatment. After the first year, 35 patients remained in hematological CR, including 5 who had stopped pegylated-IFN-2a without subsequent cytoreductive treatment. Sequential samples for %V617F monitoring, available in 29 patients, showed %V617F decrease in 26 (89.6%). Median %V617F decreased from 45% before pegylated-IFN-2a to 22.5%, 17.5%, 5%, and 3% after 12, 18, 24, and 36 months, respectively (p<0.0001). Molecular CR (JAK2V617F undetectable) was achieved in 7 patients, lasting from 6+ to 18+ months, and persisted after pegylated-IFN-2a discontinuation in 5. Final %V617F was independent of baseline characteristics. No vascular event was recorded. Those results show that pegylated-IFN-2a yields high rates of hematological and molecular response in PV with limited toxicity, and could even eliminate the JAK2 mutated clone in selected cases. Summary of the PVN1 study is available on www.ClinicalTrials.gov (identifier: NCT00241241) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera J. Clin. Oncol., November 10, 2009; 27(32): 5418 - 5424. [Abstract] [Full Text] [PDF] T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, July 23, 2009; 114(4): 759 - 763. [Abstract] [Full Text] [PDF] R. A. Mesa How I treat symptomatic splenomegaly in patients with myelofibrosis Blood, May 28, 2009; 113(22): 5394 - 5400. [Abstract] [Full Text] [PDF] G. Barosi, G. Birgegard, G. Finazzi, M. Griesshammer, C. Harrison, H. C. Hasselbalch, J.-J. Kiladjian, E. Lengfelder, M. F. McMullin, F. Passamonti, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference Blood, May 14, 2009; 113(20): 4829 - 4833. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] Interferon for Polycythemia Vera Journal Watch Oncology and Hematology, November 10, 2008; 2008(1110): 1 - 1. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020